Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston
59
×
boston blog main
boston top stories
59
×
national blog main
life sciences
biotech
national top stories
clinical trials
deals
fda
san francisco blog main
new york blog main
startups
san francisco top stories
new york top stories
san diego blog main
vc
venture capital
drugs
investing
life science
national
alnylam pharmaceuticals
event
rna interference
san diego top stories
medical device
roche
software
cancer
crispr
eli lilly
healthcare
indiana blog main
medical devices
patisiran
seattle blog main
.406 ventures
drug delivery
editas medicine
What
medicines
drug
boston
medicine
new
medical
digital
health
tech
therapeutics
fda
life
million
team
gene
rna
startup
accelerating
attend
biopharma's
biopharma’s
breakthroughs
company
future
learn
registering
sciences
xcelerating
ago
genetic
ipo
join
online
pharmaceuticals
alnylam
approval
deal
device
drugs
healthcare
Language
unset
unknown
Current search:
boston
×
" boston top stories "
×
@xconomy.com
3 years ago
Codiak Bio’s IPO Brings In $82M as Exosome Clinical Trials Begin
@xconomy.com
3 years ago
Praxis Precision Medicines Leads Way as Three More Biotechs Prep IPOs
@xconomy.com
3 years ago
Dyne’s Upsized IPO Brings In $233M for Muscle Disorders Drug R&D
@xconomy.com
3 years ago
FDA Approves Blueprint Cancer Drug Targeting RET Genetic Signatures
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
3 years ago
Dyne Eyes IPO for R&D of Genetic Medicines for Rare Muscle Diseases
@xconomy.com
3 years ago
AbbVie Exits Editas Alliance, Pruning Another Genetic Medicines Pact
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
3 years ago
Goldfinch Raises $100M for Kidney Drug Studies Now, Perhaps an IPO Later
@xconomy.com
3 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
3 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
3 years ago
Join us this Wednesday for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Backed by $100M, Praxis Aims to Turn Epilepsy Research Into New Neuro Drugs
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Join Us Online May 13 for Xcelerating Life Sciences: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
Early Bird Sale Ends Today for Xcelerating Life Sciences Boston: Biopharma’s Future in Digital Health
@xconomy.com
4 years ago
EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
4 years ago
Disc Medicine Launches With $50M to Advance New Anemia Treatments
@xconomy.com
4 years ago
UCB Stakes Out Autoimmune Territory With $2.1B Deal for Ra Pharma
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
4 years ago
Jeff Leiden, Who Shaped Vertex Into a CF Force, to Switch Roles
@xconomy.com
4 years ago
Boston Tech Watch: Vaxess, Fusion Power, Wayfair & MassChallenge
@xconomy.com
4 years ago
Boston Tech Watch: Polaris, GE, DataRobot, Facial Recognition Woes
@xconomy.com
4 years ago
Synlogic Lands $80M from Ginkgo to Ramp Up “Living Medicines” R&D
@xconomy.com
4 years ago
Laurie Glimcher To Headline Xconomy Keynote Series in Boston in September
@xconomy.com
5 years ago
Censinet Takes Off With $7.8M to Track Cyber Risks in Healthcare
@xconomy.com
5 years ago
New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug
@xconomy.com
5 years ago
CRISPR Diagnostic Race Heats Up as Sherlock Bio Launches With $35M
@xconomy.com
5 years ago
FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take
@xconomy.com
5 years ago
Editas CEO Katrine Bosley to Depart on Cusp of CRISPR Clinical Trial
@xconomy.com
5 years ago
Beta Bionics Secures $63M as AI-Driven “Pancreas” Heads to Key Tests
@xconomy.com
5 years ago
Sage Hits Mark in Postpartum Depression Phase 3 Trial, Stock Surges
@xconomy.com
5 years ago
Boston Tech Watch: Gradifi, Numerated, Jibo, Corvus, Botkeeper
@xconomy.com
5 years ago
Free of Baggage, Dicerna Cuts Another RNAi Deal and Gets $200M
@xconomy.com
5 years ago
Andreessen Leads $300M Bet on Devoted Health’s Senior Care Approach
@xconomy.com
5 years ago
Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug
@xconomy.com
5 years ago
Circulation CEO Talks Sale to LogistiCare & Amazon’s Healthcare Play
@xconomy.com
5 years ago
Six Life Science Firms Close Q3 with an IPO, More Are on the Way
@xconomy.com
5 years ago
With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug
@xconomy.com
5 years ago
In Boston’s Shadow, Rhode Island Fights for Life Science Jobs, Respect
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
First
Prev
Page 1
(current)
Next
Last